Diabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center

Similar documents
Diabetes and Heart Disease

Diabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker

2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary

Diabetes Mellitus: A Cardiovascular Disease

Established Risk Factors for Coronary Heart Disease (CHD)

When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology

Cardiovascular Complications of Diabetes

Session 21: Heart Health

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group

Chapter 18. Diet and Health

Controversies in Preventative Cardiology

Conflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines

NEW GUIDELINES FOR CHOLESTEROL

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN

SESSION 3 11 AM 12:30 PM

Cardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century September 23, 2009

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Disclosures. Outline. Metabolic Syndrome and Diabetes: Evaluating CVD Risk and Strategies for CVD Risk Reduction

Health Score SM Member Guide

Macrovascular Disease in Diabetes

7/6/2012. University Pharmacy 5254 Anthony Wayne Drive Detroit, MI (313)

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc.

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century November 2, 2016

2013 Hypertension Measure Group Patient Visit Form

Screening Results. Juniata College. Juniata College. Screening Results. October 11, October 12, 2016

!!! Aggregate Report Fasting Biometric Screening CLIENT!XXXX. May 2, ,000 participants

Clinical Recommendations: Patients with Periodontitis

Welcome and Introduction

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Also, some risk factors, such as smoking and diabetes, put you at greater risk for CHD and heart attack than others.

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.

Diabetic Dyslipidemia

Long-Term Complications of Diabetes Mellitus Macrovascular Complication

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Cardiovascular Disease Risk Factors:

Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018

Clinical Care Performance. Financial Year 2012 to 2018

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Diabetes and Concomitant Cardiovascular Disease: Guideline Recommendations and Future Directions

The Heart of Women s Health

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

STAYING HEART HEALTHY PAVAN PATEL, MD CONSULTANT CARDIOLOGIST FLORIDA HEART GROUP

SESSION 5 2:20 3:35 PM

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia

1. Most of your blood cholesterol is produced by: a. your kidneys b. your liver c. your pancreas d. food consumption (Your liver)

Cardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century October 4, 2010

Lipoprotein Particle Profile

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

MOLINA HEALTHCARE OF CALIFORNIA

No relevant financial relationships

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015

Cardiovascular Disease

How would you manage Ms. Gold

American Diabetes Association 2018 Guidelines Important Notable Points

Young high risk patients the role of statins Dr. Mohamed Jeilan

CHOLESTEROL CONTENT CREATED BY. Learn more at


The Metabolic Syndrome: Is It A Valid Concept? YES

Hot off the press. What s new and potentially relevant. Petr Polasek MD FRCPC FACC

Case Presentation. Moderator: Sharon Liu, DO Associate Internal Medicine Chief Austin Regional Clinic Austin, Texas

Diabetes 101 A Medical Assistant Training Module

Cardiovascular disease and diabetes Vascular harmony

The Diabetes Link to Heart Disease

Update on CVD and Microvascular Complications in T2D

Low carbohydrate diets- do they have a place?

The Clinical Unmet need in the patient with Diabetes and ACS

Common Diabetes-related Terms


CLINICAL OUTCOME Vs SURROGATE MARKER

American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida

Metabolic Syndrome.

Treatment to reduce cardiovascular risk: multifactorial management

Risk Factors for Heart Disease

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications

Kidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)

Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY

Cardiovascular System and Health. Chapter 15

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk

Test5, Here is Your My5 to Health Profile with Metabolic Syndrome Insight

Heart Disease and Diabetes Teaching Module

Living a Heart Healthy Life. Eleanor Stewart, MSN, RN, AGACNP-BC

HEART HEALTH AND HEALTHY EATING HABITS

Statins and Cholesterol. Noreen Devanney Primary Care Pharmacist Surrey Heath CCG

ASSeSSing the risk of fatal cardiovascular disease

Lecture 8 Cardiovascular Health Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors

Dyslipedemia New Guidelines

Clinical Practice Guideline

Coronary Artery Disease Clinical Practice Guidelines

Personal Diabetes Passport

Lipid Management 2013 Statin Benefit Groups

Steps Against Recurrent Stroke (STARS)

POST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) Term-End Examination June, 2015

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015

SIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

Hypertension and Hyperlipidemia. University of Illinois at Chicago College of Nursing

Transcription:

Diabetes and Heart Disease Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center

No conflicts of interest or financial relationships to disclose. 2

What s the problem?? Diabetes mellitus (DM) affects 1 in 10 US adults 90-95% of cases are type 2 DM DM is becoming an increasing problem in children Prevalence has increased by 30.5% between 2001-2009 Women with DM live an average of 8.2 years less than those without DM DM is considered a coronary heart disease risk equivalent 3

What is Cardiovascular Disease? Cardiovascular disease (or CVD) includes heart and blood vessel diseases diseases that affect the circulatory system.

Events*/100 person-years Diabetes Mellitus: Risk of Myocardial Infarction East-West Study 50 40 45 DM No DM 30 20 10 0 Patients with DM and no prior history of heart attack had 19a similar rate 20 of having a heart attack as patients who don t have DM but with a prior history of heart attack. Prior CHD No prior CHD 3.5 Slide adapted from acc.org *Fatal or non-fatal MI CHD=Coronary heart disease, DM=Diabetes mellitus, MI=Myocardial infarction Source: Haffner SM et al. NEJM 1998;339:229 234

Lifestyle risk factors Physical inactivity Diet Obesity Smoking 6

Metabolic risk factors High blood pressure (Hypertension, HTN) High cholesterol (dyslipidemia, hyperlipidemia) High blood sugar 7

Metabolic syndrome Need at least 3 of the following risk factors: Waist circumference >35 inches in females (>40 inches in males) HDL <50 mg/dl in females, <40 mg/dl in males Triglycerides 150 mg/dl Fasting glucose 110 mg/dl Blood pressure 130/ 85 mmhg Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 2001;285:2486-2497 8

Complications of Diabetes MICROvascular Retinopathy (most common) Neuropathy (tingling, burning, numbness) Nephropathy (kidney disease) MACROvascular Coronary heart disease (heart attack, narrowing of the heart arteries) Peripheral arterial disease Stroke 9

Mechanisms Chronic inflammation and injury Activates the immune system which leads to development of fatty plaque This can occur in the heart arteries (coronary arteries) or the arteries in the legs (peripheral arteries) Platelets are more sticky and may clump together to form a blood clot 10

Mechanisms Chronic inflammation and injury Activates the immune system which leads to development of fatty plaque This can occur in the heart arteries (coronary arteries) or the arteries in the legs (peripheral arteries) Platelets are more sticky and may clump together to form a blood clot 11

Mechanisms Inflammation IL-6 CRP SAA Infection Defense mechanisms Pathogen burden Hyperglycemia AGE Oxidative stress Subclinical Atherosclerosis Insulin Resistance HTN Endothelial dysfunction Dyslipidemia LDL TG HDL Thrombosis PAI-1 TF tpa Subclinical: not readily detected or easily seen; you do not manifest signs/symptoms of the disease yet Disease Progression Atherosclerotic Clinical Events AGE=Advanced glycation end products, CRP=C-reactive protein, CHD=Coronary heart disease HDL=High-density lipoprotein, HTN=Hypertension, IL-6=Interleukin-6, LDL=Low-density lipoprotein, PAI- 1=Plasminogen activator inhibitor-1, SAA=Serum amyloid A protein, TF=Tissue factor, TG=Triglycerides, tpa=tissue plasminogen activator Slide adapted from acc.org Source: Biondi-Zoccai GGL et al. JACC 2003;41:1071-1077

13

Take Action! 1. Know your numbers Hemoglobin A1C (HgbA1C; goal <7%) Fasting Lipid Panel (LDL<100, HDL>50, Triglycerides<150) Blood pressure (<130/80) Weight and Body Mass Index (goal BMI<25) Know your past (learn your Family History) 14

Take Action! 2. Write it down Take inventory (Keep a food log) Reduce intake of saturated and trans fats Note triggers for eating are you hungry, stressed, bored? Why am I doing this? 15

Take Action! 3. Get moving Aim to reduce body weight by 7-10% in the first year Do at least 30 minutes of moderate intensity exercise at least 5 times a week Make a schedule and keep your gym clothes and shoes in your car so you re ready to go. 16

Take Action! 3. Mind your mouth Keep it natural Avoid canned foods, deli meats, red meats, cheeses, processed and packaged foods Aim for no more than 2,400 mg/day of sodium More fruits, vegetables, unsalted nuts, fish Make more meals at home Daily intake of alcohol should be 1 drink for adult women, 2 drinks for adult men Get your family involved 17

Take Action! 4. Take your medications as prescribed And keep up with doctor s visits Ask your doctor if you would benefit from a statin (cholesterol medicine) or aspirin 18

ASCVD Risk Calculator Estimates your risk of having a heart disease or stroke in the next 10 years or your lifetime risk https://tools.acc.org/ascvd-risk-estimator/ Do not use this calculator if you have had a heart attack or stroke in the past Do not use this calculator if your LDL level is greater than 190 19

EXAMPLE 1: 45 year old woman no risk factors 20

EXAMPLE 1: 45 year old woman with diabetes and no other risk factors 21

ADA/AHA/ACCF Primary Prevention of CV Disease Antiplatelet Agent Recommendations Primary Prevention I IIa IIb III Low-dose aspirin therapy (75-162 mg/day) is reasonable for adults with DM and no previous history of vascular disease who are at increased CVD risk (10-year risk >10%) and who are not at increased risk for bleeding (based on a history of previous GI bleeding or peptic ulcer disease or concurrent use of other medications that increase bleeding risk such as NSAIDs or warfarin). Those adults with DM at increased CVD risk include most men >50 years of age or women >60 years of age who have at least one additional major risk factor.* * ADA Level C Includes those with family history of premature CVD, hypertension, smoking, dyslipidemia, or albuminuria ACCF=American College of Cardiology Foundation, ADA=American Diabetes Association, AHA=American Heart Association, CV=Cardiovascular, CVD=Cardiovascular disease, DM=Diabetes mellitus, GI=Gastrointestinal, NSAIDs=Non-steroidal anti-inflammatory drugs Source: Pignone M et al. Circulation 2010;121:2694-2701

https://statindecisionaid.mayoclinic.org/ 23

Choice of Antidiabetic Agents Empagliflozin (EMPA-REG OUTCOME trial) Liraglutide (LEADER trial) Ongoing trials to evaluate CV effects of different agents: DECLARE-TIMI 58 (Dapagliflozin) CANVAS (Canagliflozin) REFORM (SGLT-2 Inhibitors) 24

Coronary artery calcium (CAC) CAC scan or Heart scan Does not require iv contrast Simple CT scan of the heart arteries Looks for presence of calcium Calcium is a marker of atherosclerosis or plaque in the arteries Can improve adherence to medication and lifestyle changes 25

Take Action! 5. Please stop smoking Helpful resources: Your primary care doctor www.smokefree.gov cdc.gov/tobacco www.lung.org/stop-smoking 26

Quick tips Habits are key This is a lifestyle change Knowledge is power Don t be afraid to ask for help. 27

Resources Centers for Disease Control (CDC) American Diabetes Association (ADA) American Heart Association (AHA) 28

Rush Heart Center for Women 29

30

Thank you for your attention! 31